Literature DB >> 24614594

Rheumatoid arthritis: When TNF inhibitors fail in RA--weighing up the options.

Lucia Silva-Fernandez1, Kimme Hyrich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24614594     DOI： 10.1038/nrrheum.2014.34

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.

Authors:  Carine Salliot; Axel Finckh; Wanruchada Katchamart; Yan Lu; Ye Sun; Claire Bombardier; Edward Keystone
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

2.  Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.

Authors:  Juan J Gomez-Reino; Jose Ramon Maneiro; Jorge Ruiz; Rosa Roselló; Raimon Sanmarti; Ana Belen Romero
Journal:  Ann Rheum Dis       Date:  2012-06-26       Impact factor: 19.103

3.  Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Authors:  Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Cem Gabay; Piet L C M van Riel; Dan C Nordström; Juan Gomez-Reino; Karel Pavelka; Matija Tomsic; Tore K Kvien; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2011-05-12       Impact factor: 19.103

4.  Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

Authors:  Juan J Gómez-Reino; Carlos Rodríguez-Lozano; Cristina Campos-Fernández; María Montoro; Miguel Ángel Descalzo; Loreto Carmona
Journal:  Ann Rheum Dis       Date:  2011-10-13       Impact factor: 19.103

5.  Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Authors:  Moetaza M Soliman; Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Darren M Ashcroft
Journal:  J Rheumatol       Date:  2011-12-15       Impact factor: 4.666

6.  Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Authors:  Katerina Chatzidionysiou; Johan Askling; Jonas Eriksson; Lars Erik Kristensen; Ronald van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

7.  Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.

Authors:  K Chatzidionysiou; R F van Vollenhoven
Journal:  Scand J Rheumatol       Date:  2013-01-03       Impact factor: 3.641

8.  Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Authors:  Moetaza M Soliman; Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Darren M Ashcroft
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

9.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors:  A Finckh; A Ciurea; L Brulhart; B Möller; U A Walker; D Courvoisier; D Kyburz; J Dudler; C Gabay
Journal:  Ann Rheum Dis       Date:  2009-05-04       Impact factor: 19.103

10.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.

Authors:  P Emery; J E Gottenberg; A Rubbert-Roth; P Sarzi-Puttini; D Choquette; V M Martínez Taboada; L Barile-Fabris; R J Moots; A Ostor; A Andrianakos; E Gemmen; C Mpofu; C Chung; L Hinsch Gylvin; A Finckh
Journal:  Ann Rheum Dis       Date:  2014-01-17       Impact factor: 19.103
  10 in total
  3 in total

Review 1.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

2.  Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption.

Authors:  Charla R Fischer; Maya Mikami; Hiroshi Minematsu; Saqib Nizami; Heon Goo Lee; Danielle Stamer; Neel Patel; Do Yu Soung; Jung-Ho Back; Lee Song; Hicham Drissi; Francis Y Lee
Journal:  J Orthop Res       Date:  2017-07-18       Impact factor: 3.494

Review 3.  Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment.

Authors:  Valentina Pegoretti; Wia Baron; Jon D Laman; Ulrich L M Eisel
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.